Acta medica Indonesiana最新文献

{"title":"Olfactory and Gustatory Recovery Time Evaluation of COVID-19: A Systematic Review and Meta-Analysis.","authors":"Mohadeseh Poudineh, Amirhesam Amirbeik, Mohammad Dehghani Firouzabadi, Mahsa Hajizadeh, Farima Kahe, Sepideh Babaniamansour, Amirhossein Poopak, Farbod Zahedi Tajrishi, Niloofar Deravi, Mohammad Rahmanian, Hamidreza Ghasemirad, Mahta Malek, Masoud Noroozi, Mobina Fathi, Kimia Keylani, Ali Dehghani Firouzabadi, Ghader Dargahi Abbasabad, Forough Yazdanian, Sara Ramezanpour, Amirmohammad Babaniamansour, Faryar Zahedi Tajrishi, Soheil Mohammadi, Golnoosh Ansari, Fatemeh Dehghani Firouzabadi, David M Yousem","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Olfactory dysfunction is a common symptom of Coronavirus disease 2019 (COVID-19). In this study, we aimed to evaluate the recovery rate and duration of these symptoms in COVID-19patients.</p><p><strong>Methods: </strong>This systematic review was conducted by searching PubMed and Google Scholar from April 1st, 2020, until October 1st, 2022, using the terms ''COVID-19'' OR ''COV-2,'' OR ''Coronavirus 2'' OR coronavirus AND ''loss of smell'' OR Anosmia OR Hyposmia OR olfaction OR ''olfactory loss'' AND ageusia OR Hypogeusia OR dysgeusia OR ''gustatory loss'' OR gustation OR ''loss of taste''. The references of included studies were also manually screened. Random-effects meta-analysis was performed.</p><p><strong>Results: </strong>One hundred and twenty-five studies with test-confirmed COVID-19 infection from 31 countries were included. 62 publications which reported data on loss of taste were used to estimate patients' recovery rate in 13700 COVID-19 patients. Accordingly, the time to recovery of loss of taste among COVID-19 patients ranged from 2±0.352 to 43.6 ± 28.5 days. The estimated overall pooled recovery rate of loss of taste among COVID-19 patients was 74%. The estimated overall pooled time to recover loss of taste among COVID-19 patients was 11.44 days [95% CI 8.11, 14.77(]. 90 publications which reported data on loss of smell were used to estimate patients' recovery rate in 20027 COVID-19 patients. Accordingly, the time to recover the loss of smell among COVID-19 patients ranged from 2.44±0.352 to 31.9 ± 30.7 days The estimated overall pooled recovery rate of loss of smell among COVID-19 patients was 72%. The estimated overall pooled time to recover loss of smell among COVID-19 patients was 12.87 days [95% CI)1011, 15.64(].</p><p><strong>Conclusion: </strong>The recovery rate of loss of smell and taste among COVID-19 patients was high globally, and time to recovery of loss of smell and taste among COVID-19 patients usually was less than 2 weeks; regional differences supported the relevance of these symptoms as important markers. Health workers must consider smell and taste symptoms as suspicion indices for the empirical diagnosis of COVID-19 infection and reassure patients with their high recovery rate in a short period of time.</p>","PeriodicalId":6889,"journal":{"name":"Acta medica Indonesiana","volume":"57 1","pages":"18-43"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Colchicine in Reducing Reperfusion Injury in STEMI Patients Who Undergo Primary Percutaneous Coronary Intervention: A Randomized Clinical Trial.","authors":"Birry Karim, Idrus Alwi, Mohammad Yamin, Merci Monica Pasaribu, Kuntjoro Harimurti, Nafrialdi Nafrialdi, Taufik Indrajaya, Rivaldo Rivaldo","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Inflammation plays a role in ST-segment elevation myocardial infarction (STEMI), especially in reperfusion injury (RI). Colchicine, an anti-inflammatory drug, can suppress inflammation during RI. We assessed the effectiveness of administering colchicine to STEMI patients undergoing primary percutaneous coronary intervention (PPCI) in suppressing RI events.</p><p><strong>Methods: </strong>This study was a randomized, double-blind, placebo-controlled clinical trial conducted in a multicenter manner at two hospitals in Jakarta with IKPP facilities from December 2022 to April 2023. STEMI patients that underwent PPCI received 2 mg of colchicine as a loading dose and a maintenance dose of 0.5 mg every 12 hours for two days or amylum at a similar dose. Patients were observed for RI events (low-flow thrombolysis in myocardial infarction (0-2) during angiography procedure, reperfusion arrhythmia, cardiogenic shock, or persistent chest pain).</p><p><strong>Results: </strong>Seventy-seven STEMI patients with a mean age of 55.2 ± 9.9 years underwent PPCI. Of these patients, 37 received colchicine, and 40 received a placebo. Most subjects were male (77.5%), suffered three-vessel disease (44.15%), and occlusion in left anterior descending coronary artery (53.24%). Colchicine was found to fail to reduce the incidence of ischemia-RI (51.5% vs. 42.4%; p = 0.437). Analysis of comorbidities (hypertension, chronic kidney disease, diabetes mellitus, and obesity) and angiography results (vessel disease, lesion diameter, and culprit artery) failed to demonstrate a statistical difference in RI. Side effects were similar in the colchicine and placebo groups (21.6% vs. 15%).</p><p><strong>Conclusion: </strong>Colchicine administration in STEMI patients undergoing PPCI failed to reduce RI.</p>","PeriodicalId":6889,"journal":{"name":"Acta medica Indonesiana","volume":"57 1","pages":"11-17"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scrofuloderma of the Penis: Unveiling a Rare Case of Cutaneous Tuberculosis.","authors":"Theo Audi Yanto, Edwin Raja Pardamean Lumban Tobing, Billie Edgara Herijanto, Jean Andrina Liem, Mohammad Zuhriansyah Sabran","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Tuberculosis (TB) is a major worldwide health concern, with 10.4 million new cases reported each year. Extrapulmonary tuberculosis (EPTB) accounts for 20% of all occurrences, with cutaneous tuberculosis (CTS) accounting for just 1-2%. Scrofuloderma is the most prevalent kind of secondary CTS, and it commonly starts in the underlying lymph nodes, bones, or joints.Here, we describe the case of a 35 years old man presenting with a solitary nodule necrotic ulcer that happens 4 days before going to the hospital. The skin biopsy from the lesion was suggestive of TB scrofuloderma. Scrofuloderma typically presents as subcutaneous nodules that ulcerate and form sinus tracts. Diagnosis is challenging, often requiring histopathological confirmation due to potential negative microbiological results. In this case, the atypical penile appearance and the patient's history of an invasive operation aided in the diagnosis. Diabetes mellitus-related immune weakness increased the patient's susceptibility to cutaneous tuberculosis. This case demonstrates the wide range of cutaneous tuberculosis presentations and the significance of extensive diagnostic techniques, particularly in unusual patients. It also emphasizes the increased risk of tuberculosis in immunocompromised people, such as those with diabetes mellitus.</p>","PeriodicalId":6889,"journal":{"name":"Acta medica Indonesiana","volume":"57 1","pages":"124-127"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sticky Platelet Syndrome as a Cause of Recurrent Miscarriages: A Rare Case Report.","authors":"Dedy Kristofer Simangunsong, Alvina Widhani, Ardhi Rahman Ahani, Eirene Simbolon, Hadiki Habib","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Sticky platelet syndrome (SPS) is a hereditary disorder. SPS can cause pregnancy complications, such as recurrent miscarriages. However, proper management can prevent the incidence of recurrent miscarriages. Here, we describe a case of a woman who lost her fifth first-trimester pregnancy, and upon assessment, we discovered SPS. The 33-year-old woman underwent consultation with an obstetrician because of her history of five first-semester miscarriages. Gynecology ultrasound, infection parameters, hormonal and metabolic panels, and autoimmune workup were all found to be normal; however, vitamin D deficiency was identified as was SPS from a platelet aggregation test. The patient was then treated with clopidogrel and vitamin D3 supplementation. She became pregnant after five months of treatment. Her pregnancy was normal and she went into delivery at 40 weeks gestation with no maternal or fetal complications.</p>","PeriodicalId":6889,"journal":{"name":"Acta medica Indonesiana","volume":"57 1","pages":"81-86"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-inflammatory Therapy Before Reperfusion Therapy in Patients with Ischemic Vascular Disease on the Incidence of Ischemic Reperfusion Injury: An Evidence-Based Case Report.","authors":"Dono Antono, Ade Gautama, Nindya P B S Utami","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Reperfusion serves as a mainstay therapy in almost all ischemic vascular diseases (IVD), but reperfusion may enhance cell damage after an ischemic period time. Increased ROS and inflammatory markers, decreasing organ function parameters, along with systemic inflammatory response and multi-organ damage may occur in ischemic reperfusion injury (IRI). Unfortunately, this series of events is unpredictable and sudden, causing high mortality in patients with IRI. Due to the significant role of inflammation in IRI, how is the effectiveness of anti-inflammatory agents administered before reperfusion therapy to prevent IRI? To know the efficacy of anti-inflammatory agents administered before reperfusion therapy to prevent IRI.</p><p><strong>Methods: </strong>A systematic search was conducted in databases (Pubmed, EMBASE, Scopus) and was later selected according to predetermined inclusion and exclusion criteria. Studies included later critically appraised using the CEBM Oxford questionnaire for randomized control trials and systematic review.</p><p><strong>Results: </strong>Seven studies were included among 1072 studies found in early searching. Six of the studies are randomized control trials, and one is a meta-analysis of randomized control trials. Methylprednisolone, pexelizumab, tirilazad mesylate, and N-acetylcysteine are known anti-inflammatory agents applicable in humans. The highest effectiveness of anti-inflammatory agents is methylprednisolone, with a relative risk reduction (RRR) of 75-85%. Besides that, pexelizumab also had an RRR of 27%, and tirilazad-mesylate had an RRR of 18%. N-acetylcysteine is not effective in preventing IRI. IL-6 levels postoperatively also decreased significantly in patients given anti-inflammatory agents before reperfusion therapy. There are no side effects of the intervention reported.</p><p><strong>Conclusion: </strong>Anti-inflammatory agent administration before reperfusion therapy effectively prevents IRI. The choices of anti-inflammatory agents recommended are methylprednisolone, pexelizumab, and tirilazad-mesylate. Anti-inflammatory agent administration before reperfusion therapy is recommended.</p>","PeriodicalId":6889,"journal":{"name":"Acta medica Indonesiana","volume":"57 1","pages":"128-139"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Vitamin D and Its Receptor Signaling in Diabetic Nephropathy and the Current Status of Research: A Literature Review.","authors":"Qiaoya He, Jiaqi An, Xinze Liu, Li Zhuo","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Diabetic kidney disease (DKD) is one of the common and serious complications of diabetes mellitus, with a complex pathogenesis and a lack of ideal treatment options in clinical practice. In recent years, the protective role of vitamin D and its receptor signaling pathway in DKD has garnered widespread attention. Vitamin D plays an important role in the onset and progression of DKD by participating in the regulation of insulin secretion, inhibiting inflammatory responses, attenuating podocyte injury, modulating the renin-angiotensin system (RAS), and inhibiting renal interstitial fibrosis through its receptor (VDR). Studies on the use of vitamin D and its receptors in DKD have increased gradually in recent years, with a focus on the development of vitamin D analogs and the clinical application of VDR activators. This study reviewed the mechanisms of vitamin D and its receptor in diabetic nephropathy, as well as the potential for therapeutic applications and associated adverse effects. It also analyzed current research hotspots and development trends based on bibliometrics. Future research should focus on further optimizing vitamin D-based therapeutic strategies to achieve better clinical efficacy and safety.</p>","PeriodicalId":6889,"journal":{"name":"Acta medica Indonesiana","volume":"57 1","pages":"113-123"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcome of Patients with Metabolic-Associated Fatty Liver Disease Who Are Infected with SARS-CoV-2: A Meta-Analysis.","authors":"Chyntia Olivia Maurine Jasirwan, Dyah Purnamasari, Alvina Widhani, Tasya Kamila","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Metabolic-associated fatty liver disease (MAFLD) is excess fat accumulation in the liver due to metabolic syndrome. Coronavirus disease 2019 (COVID-19) is an infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 not only attacks the respiratory system but also involves systemic and extra-pulmonary organ disorders, including liver disorders. This review evaluates the severity of COVID-19, mortality, and length of hospital stays of patients with MAFLD who were infected with SARS-CoV-2.</p><p><strong>Methods: </strong>Literature searches were conducted through various online databases. The risk of bias assessment was conducted by two researchers using the Newcastle Ottawa Scale tool for NRSI studies, and any discrepancies were resolved by another team member. The meta-analysis was performed using Revman 5.4.1 and results were presented in forest plot by calculating the pooled odds ratio or mean difference between the MAFLD and non-MAFLD groups from the evaluated studies with a 95% CI.</p><p><strong>Results: </strong>The results of the meta-analysis using a fixed-effect model from seven studies showed that COVID-19 patients with MAFLD were associated with a higher mortality compared to those without MAFLD (OR 1.41, 95% CI 1.19-1.69, p=0.01, I2 48). However, there were no differences in COVID-19 severity (OR 3.12, IK95% 0.89-11.03, p=0.08, I2 92) and length of hospital stay (MD 1.27, CI95% 0.03-2.52, p=0.04, I2 80) between the two groups.</p><p><strong>Conclusion: </strong>MAFLD patients infected with SARS-CoV-2 were associated with higher mortality than non-MAFLD patients, but they were not associated with greater severity of COVID-19 nor a longer duration of hospitalization.</p>","PeriodicalId":6889,"journal":{"name":"Acta medica Indonesiana","volume":"57 1","pages":"61-73"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143951956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Aging Population and Dementia: The Need for Comprehensive Palliative Care.","authors":"Jessica Marsigit, Valentine Natasya Moenardi, Rudi Putranto, Hamzah Shatri, Vinandia Irvianita, Edward Faisal","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Dementia is a progressive condition that gradually impairs cognitive function, memory, and daily living skills. This disease not only impacts the individual but also has significant consequences for their families and caregivers. The global prevalence of dementia is on the rise, including in Indonesia. It's estimated that approximately 1.2 million people in Indonesia are currently living with dementia, a number projected to quadruple by 2050. Patients with dementia often experience a range of symptoms and complications, including pain, difficulty eating, shortness of breath, and susceptibility to infections. For those in advanced stages of the disease, family and caregivers play a crucial role in their well-being. However, this role can be emotionally taxing, making support essential. Palliative care offers a promising approach to enhancing the quality of life for both dementia patients and their families. By prioritizing symptom management, psychological support, and respecting patient autonomy, palliative care can help alleviate suffering and promote well-being throughout the disease's progression.</p>","PeriodicalId":6889,"journal":{"name":"Acta medica Indonesiana","volume":"57 1","pages":"140-149"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Impact of Central Post-Stroke Pain on Quality of Life Among Stroke Survivors: A Cross-Sectional Study.","authors":"Sekplin A S Sekeon, Asri Adisasmita, Mondastri K Sudaryo, Aida R Tantri","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Stroke continues to be a significant public health challenge. Central post-stroke pain (CPSP) is a notable aspect of post-stroke pain that not only causes physical discomfort but also affects psychological well-being, leading to a reduced quality of life. The objective of this was to assess the prevalence of CPSP and its relationship with quality of life.</p><p><strong>Methods: </strong>This hospital-based cross-sectional study was conducted between August and December 2023 in Manado, Indonesia, the study involved the consecutive recruitment of stroke patients. CPSP diagnosis adhered to the 2017 criteria set forth by the American Pain Society, while quality of life was evaluated using the Indonesian version of the Stroke Specific Quality of Life (SS-QoL) scale.</p><p><strong>Results: </strong>The study comprised 166 stroke patients, revealing that 30.1% experienced CPSP. Notably, there was a significant difference in mean SS-QoL scores based on both the severity of the stroke and the presence of depression. Within the CPSP group, a significant variation in SS-QoL summary scores was observed between male and female patients. Those with CPSP reported significantly lower mean scores in the Thinking and Energy categories. However, there was no significant difference in the overall SS-QoL scores between CPSP and non-CPSP patients.</p><p><strong>Conclusion: </strong>In summary, stroke patients suffering from depression, greater severity of stroke, and those experiencing burning or pressure-like sensations are at an increased risk of having a lower quality of life.</p>","PeriodicalId":6889,"journal":{"name":"Acta medica Indonesiana","volume":"57 1","pages":"52-60"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microsatellite Status, Tumor Budding, CD3 and CD8 T Cell Densities in Relation to Invasiveness, Lymph Node Involvement in Colorectal Adenocarcinoma.","authors":"Rebecca Noerjani Angka, Aru Wisaksosno Sudoyo, Nurjati Chairani Siregar, Wifanto Saditya Jeo, Melva Louisa, Demak Lumban Tobing","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Aside from the factors more commonly known as predictors in colorectal cancer, there are 3 additional less well-known factors, i.e., tumor budding (TB), T cell densities and loss of MMR protein expression, the aforementioned three factors are known to be independent predictive factors in CRC survival. In this study association of TB, T cell densities and loss of MMR protein were examined to see the association with differentiation, tumor location, invasiveness and lymph node invasiveness.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted using 68 CRC Formalin Fixed Paraffin Embedded samples from patients who underwent removal surgeries with the diagnosis of adenocarcinoma not otherwise specified. TB counts were identified by immunohistochemical staining using Pan-Cytokeratin AE1/AE3 and were categorized into low and high. MMR protein loss was analyzed using antibodies MLH1 and MSH6 categorized as positive and negative, then classified into Microsatellite Stable (MSS) and Microsatellite Instability (MSI). CD3 and CD8 T cell densities were identified using CD3 Biocare Medical and CD8 Biocare, was categorized into low and high. Secondary data from medical records were collected and analyzed using SPSS 25.</p><p><strong>Results: </strong>A significant relationship was found between tumor budding with the depth of invasion and lymph node involvement (p=0.021 and 0.020).</p><p><strong>Conclusion: </strong>Tumor budding (TB) plays a role in the depth of invasion and lymph node involvement in CRC but has no significant relationship with CD3/CD8 densities, differentiation, location, and MMR status. There was also no significant relationship between MMR status with differentiation, location, depth of invasion, lymph node involvement, and TB.</p>","PeriodicalId":6889,"journal":{"name":"Acta medica Indonesiana","volume":"57 1","pages":"44-51"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}